What impact does bundling have on the treatment of dialysis patients? This session reviews current multidisciplinary approaches for treatment of anemia and hyperphosphatemia and examines the impact that bundled reimbursement has on the quality of care. The influences that the Affordable Care Act can have on ESRD and CKD reimbursement are also addressed.

Contact hours available until 9/22/2015.

Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online CNE evaluation.

Conflict of Interest Disclosure:
Myra Kleinpeter discloses that she received grant/research support from Bristol Myers Squibb; is a consultant/member of the speakers' bureau for Gilead Sciences, Inc.; and serves on the advisory board for Gilread Sciences, Amgen, and Fresenius.

Conference Committee Disclosures:
Dawn Koonkongsatian – Employee, Fresenius Medical Care
Kristin Larson – Employee, NxStage Medical
Denise Murcek – Employee, Fresenius Medical Care
Beth St. John - Employee, Fresenius Medical Care
Lucy Todd – Employee, Baxter Healthcare; Kyra Trappett – Employee, DaVita

Commercial Support and Sponsorship:
Supported by an unrestricted educational grant from Keryx Biopharmaceuticals, Inc.

Accreditation Statement:
American Nephrology Nurses’ Association is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

ANNA is a provider approved by the California Board of Registered Nursing, provider number CEP 00910.

Objectives:

Describe current multidisciplinary approaches to the management of anemia and hyperphosphatemia.
Discuss the impact of bundled reimbursement on the quality of anemia and hyerphosphatemia management.
Determine the influences that the PPACA may have on ESRD and CKD reimbursement.

Sharon Stall MPH, RD, CSR, CDN

Appearances